Evaluate the Effects of DalcetrapibDalcetrapib is a CETP inhibitor which was being developed by Hoffmann–La Roche until May 2012 on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)Acute Coronary Syndrome.
CRITERIA LIST/ QUALIFICATIONS:
Subjects recently hospitalized for ACS (between 4 and 12 weeks following the index event).
AA genotype at variant gene as determined by Genotype Assay testing.
Clinically stable, ie, free of ischemic symptoms at rest or with minimal exertion for at least 1 week prior to randomization.